Current Affairs - Science - Discussion

Malaria is the disease targeted by Coartem Baby, the first WHO-prequalified drug specifically designed for newborns and infants. Developed by Novartis in collaboration with the Medicines for Malaria Venture (MMV), this medication addresses a critical gap in pediatric treatment. It uses an artemether-lumefantrine combination and is suitable for infants weighing between 2 to 5 kilograms. The disease remains a major global health concern, causing millions of cases and deaths annually, especially among children under five in Africa, making this innovation a significant breakthrough.